Mineralys Therapeutics (MLYS) Total Current Liabilities (2022 - 2026)

Mineralys Therapeutics has reported Total Current Liabilities for 5 years, with the latest figure at $14.7 million in Q1 2026.

• Quarterly Total Current Liabilities rose 9.95% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 9.95% YoY) and the FY2025 annual result came in at $15.1 million, up 3.19% from the prior year.
• Total Current Liabilities declined to $14.7 million in Q1 2026 per MLYS's latest filing, from $15.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.3 million in Q3 2024 and troughed at $6.2 million in Q2 2023.
• A 5-year average of $16.5 million and a median of $14.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 357.5% in 2024, then tumbled 30.3% in 2025.
• Over 5 years, Total Current Liabilities stood at $8.1 million in 2022, then advanced by 29.94% to $10.5 million in 2023, then surged by 39.73% to $14.6 million in 2024, then climbed by 3.19% to $15.1 million in 2025, then slipped by 2.61% to $14.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $14.7 million, $15.1 million, and $23.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.